TellBio, Inc., a biotechnology company focused on cancer detection, has recently published two manuscripts that highlight the applications of its TellDx platform in prostate cancer and advanced breast cancer. The publications, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells," were featured in Cell and Breast Cancer Research and Treatment, respectively.
The TellDx technology is a unique system that allows for molecular analysis of circulating tumor cells (CTCs) in different types of cancer patients. This technology provides valuable insights into cancer progression and helps guide therapeutic selection. In the case of prostate cancer, CTCs isolated with TellDx showed epigenetic changes that silenced immune surveillance genes while sparing proliferation-associated genes. This finding could potentially explain drivers of cancer progression and aid in early detection.
In a study on advanced breast cancer, CTCs derived from TellDx were used to evaluate the efficacy of a novel drug called elacestrant.